Juniper Publishers-Cancer Therapy Oncology International Journal

  Cancer Therapy & Oncology- Juniper Publishers                                                      Abstract Introduction Lymphoma has been historically divided into a Hodgkin and Non-Hodgkin variety. There are reported cases of Hemolytic Anemia in Non- Hodgkin Lymphoma but Hodgkin Lymphoma very rarely also present with Hemolytic Anemias. Case presentation A 27-year-old African woman presented with chronic fatigue, dyspnoea, jaundice and Splenomegalie. Her blood work revealed severe anaemia (haemoglobin, 4.9 g/dl) with biochemical evidence of haemolysis. A direct Coomb's test was reported positive. A biopsy of the lymph nodes in the neck confirmed Hodgkin Lymphoma. Initial therapy consisted of intravenous methyl prednisolone and switched over to Oral Prednisolone. However, the patient came back with raised sugar levels and there was no clinical...

  Cancer Therapy & Oncology International Journal Abstract The medical devices that are designated to be marketed need to go through a clearance process set forth by FDA. The Premarket notification (PMN) or 510(k) is the most common regulatory pathway in US but poses many challenges to medical device manufacturers. FDA has cleared more than 1, 40,000 medical devices since 1976. This is a clearance process, and not an approval, for medical devices. 510(K) submission has a purpose, a process and should be well understood in order to avoid unnecessary delays and failures. Keywords: Medical device; Regulation; FDA; 510(K); Substantially Equivalent Abbreviations: FDA: Food and Drug Administration, PMA: Premarket Approval; SE: Substantially Equivalent; Introduction Getting a clearance letter from FDA on 510(K) for a medical device is a milestone and the ultimate goal for any medical device manufacturer, be it a small ...

  Cancer Therapy & Oncology International Journal Abstract Neurofibromatosis was first described in 1882 by Friedrich Daniel von Reckling hausen, a German pathologist. Neurofibroma is a benign peripheral nerve sheath tumor that consists of Schwann cells, associated or unassociated with axons, perineural cells, and fibroblasts. Whenever possible, the treatment of choice should be surgical, but the management depends on the location and growth pattern. We present the case of a patient with left axillary neurofibroma without neurofibromatosis (NF) in whom surgery was delayed due to involvement of the brachial plexus, so was sent to radiotherapy, planned and treated with volumetrically modulated arc therapy (VMAT). Keywords: Neurofibroma; VMAT; Radiotherapy; Axillary Tumor; INCART Abbreviations: NF: Neurofibromatosis; VMAT: Volumetrically Modulated Arc Therapy; CRO: Radiation Oncology Center; INCART: Institute Rosa Emilia Sánchez Pérez de Tavares; ...

  Cancer Therapy & Oncology International Journal Abstract Neurofibromatosis type 1 (NF1), formerly known as von Recklinghausen’s disease is a nervous system tumor disorder of variable expressivity. Malignant solitary fibrous tumors (SFT) are rare spindle cell soft tissue tumors. We report a case of a 35-year-old male who presented clinically with NF1 and a mass that mimicked a nerve sheath tumor radiologically, but pathologically was, in fact, a malignant solitary fibrous tumor. Based on a literature review, the association between NF1 and malignant SFT has never been published. Keywords: Neurofibromatosis type 1; Malignant solitary fibrous tumor Abbrevations: SFT: Solitary Fibrous Tumors; NF1: Neurofibromatosis type 1 Mini Review Neurofibromatosis type 1 (NF1) is a multisystem disease characterized by cutaneous findings, as well as benign and malignant tumors o...

  Cancer Therapy & Oncology International Journal Abstract Introduction and Objective: Clinical studies have demonstrated synergistic antitumor effects of chemotherapy (CT) and zoledronic acid (AZ). In the essay Neo - AZURE, to determine whether the addition of AZ to neoadjuvant chemotherapy gives compléte histological responses. We report a prospective evaluation comparing compléte pathological response between different subs - biomolecular groups. Methods: From 2012 to 2014, 432 patients received neoadjuvant chemotherapy + AZ. The main objective is the complete histologic response. Secondary endpoints were clinical response according to RECIST criteria, estimate the overall survival of patients targeted by the study, assess bone density before and at the end of chemotherapy, the side effects associated with the treatment protocol, and Quality life Results: histologic complete response with zoledronic acid was 40.13% .the higher in the subgro...

  Cancer Therapy & Oncology International Journal Abstract Introduction and Objective: This study was aimed to evaluate the QOL among BCS who receiving various treatment strategies in Teaching Hospital, Karapitiya (THK). Method: This cross sectional study was performed with conveniently selected 142 BCS (Mean age (SD) - 55 (10.29) years) at oncology unit of THK during July 2016 using WHOQOL-BREFF questionnaire. Results: Among the studied BCS, 32.4% were studied up to O/L and 61.3% were married. 76.8% were unemployed and 38.7% had monthly income between Rs 10,000-30,000. 51.4% were living with their husband and children and 93% were Buddhist. 34.5% had undergone to CT. Mean (SD) of physical (PD), psychological (PsD), social (SD) and environmental (ED) domains were 47.79 (11.20), 42.17 (15.19), 48.86 (15.68) and 51.83 (13.61) respectively. Age, marital status, level of education and monthly income and current treatments were significantly affect...